Hofbauer LC - Search Results

1

The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis.

Hofbauer LC, Heufelder AE. Hofbauer LC, et al. Arthritis Rheum. 2001 Feb;44(2):253-9. doi: 10.1002/1529-0131(200102)44:2<253::AID-ANR41>3.0.CO;2-S. Arthritis Rheum. 2001. PMID: 11229454 Review. No abstract available.

2

Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.

Hofbauer LC, Heufelder AE. Hofbauer LC, et al. Eur J Endocrinol. 1998 Aug;139(2):152-4. doi: 10.1530/eje.0.1390152. Eur J Endocrinol. 1998. PMID: 9724069 Review. No abstract available.

3

Osteoprotegerin: a novel local player in bone metabolism.

Hofbauer LC, Heufelder AE. Hofbauer LC, et al. Eur J Endocrinol. 1997 Oct;137(4):345-6. doi: 10.1530/eje.0.1370345. Eur J Endocrinol. 1997. PMID: 9368500 Review. No abstract available.

4

Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.

Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S. Hofbauer LC, et al. Biochem Biophys Res Commun. 2001 Jan 12;280(1):334-9. doi: 10.1006/bbrc.2000.4130. Biochem Biophys Res Commun. 2001. PMID: 11162519

5

Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).

Hofbauer LC. Hofbauer LC. Ann Endocrinol (Paris). 2006 Apr;67(2):139-41. doi: 10.1016/s0003-4266(06)72569-0. Ann Endocrinol (Paris). 2006. PMID: 16639364 No abstract available.

6

The OPG/RANKL/RANK system in metabolic bone diseases.

Hofbauer LC, Kühne CA, Viereck V. Hofbauer LC, et al. J Musculoskelet Neuronal Interact. 2004 Sep;4(3):268-75. J Musculoskelet Neuronal Interact. 2004. PMID: 15615494 Review.

7

Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.

Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Sattler AM, et al. Among authors: hofbauer lc. Calcif Tissue Int. 2004 Jan;74(1):103-6. doi: 10.1007/s00223-003-0011-y. Epub 2003 Oct 6. Calcif Tissue Int. 2004. PMID: 14523602 Review.

8

Serum measurement of osteoprotegerin--clinical relevance and potential applications.

Hofbauer LC, Schoppet M. Hofbauer LC, et al. Eur J Endocrinol. 2001 Dec;145(6):681-3. doi: 10.1530/eje.0.1450681. Eur J Endocrinol. 2001. PMID: 11720890 No abstract available.

9

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.

Hofbauer LC, Neubauer A, Heufelder AE. Hofbauer LC, et al. Cancer. 2001 Aug 1;92(3):460-70. doi: 10.1002/1097-0142(20010801)92:3<460::aid-cncr1344>3.0.co;2-d. Cancer. 2001. PMID: 11505389 Review.

10

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE. Hofbauer LC, et al. J Mol Med (Berl). 2001 Jun;79(5-6):243-53. doi: 10.1007/s001090100226. J Mol Med (Berl). 2001. PMID: 11485016 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results